Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ATF4 | P18848 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1008237 | 1.00 | SMN1; SMN2 (0.51) | SMN1; SMN2GAAL3MBTL1TDP1MAPT | |
| Hydrochloric Acid SCHEMBL11539543 | 0.93 | GAA (0.47) | SMN1; SMN2GAAL3MBTL1TDP1MAPT | |
| SCHEMBL19666875 | 0.81 | MAOB (0.50) | GAAMAPTRAB9ANPC1 | |
| SCHEMBL19666874 | 0.81 | MAOB (0.50) | GAAMAPTRAB9ANPC1 | |
| SCHEMBL4033187 | 0.81 | MAPT (0.51) | SMN1; SMN2GAAL3MBTL1TDP1MAPT | |
| SCHEMBL1581040 | 0.80 | GAA (0.53) | GAAL3MBTL1 | |
| SCHEMBL1581041 | 0.80 | GAA (0.53) | GAAL3MBTL1 | |
| Hydrochloric Acid SCHEMBL836698 | 0.78 | GAA (0.51) | GAAL3MBTL1 | |
| SCHEMBL11155756 | 0.76 | TDP1 (0.56) | SMN1; SMN2GAAL3MBTL1TDP1MAPT | |
| SCHEMBL1816835 | 0.76 | SMN1; SMN2 (0.58) | SMN1; SMN2L3MBTL1TDP1MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044069-B2 | Compounds as calcium channel blockers | ABBOTT LABORATORIES (US) | 2011-10-25 | — | — | US | disclosed |
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2269990-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | disclosed |
| US-7435750-B2 | Method of using substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7041685-B2 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| US-20050154012-A1 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2005-07-14 | — | — | US | disclosed |
| US-6897306-B2 | 3-heterocyclylpropanohydroxamic acids | PFIZER PRODUCTS, INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1240152-B1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LTD (GB) | 2004-12-08 | — | — | EP | disclosed |
| EP-1406632-A2 | SUBSTITUTED 3-ARYL-5-ARYL- 1,2,4]-OXADIAZOLES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20010021718-A1 | Procollagen C-proteinase inhibitors | PFIZER INC. | 2001-09-13 | — | — | US | disclosed |
| WO-2001047901-A1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LIMITED (GB) | 2001-07-05 | — | — | WO | disclosed |
| US-6166020-A | Aryl and heteroaryl alkoxynaphthalene derivatives | PFIZER INC. (US) | 2000-12-26 | — | — | US | disclosed |
| US-5821245-A | Use of naphthalene derivatives in treating lung carcinoma | PFIZER INC. (US) | 1998-10-13 | — | — | US | disclosed |
| EP-0795328-A1 | Use of naphthalene derivatives in treating lung carcinoma | PFIZER INC. (US) | 1997-09-17 | — | — | EP | disclosed |
| EP-0590415-B1 | 1,2,4-Oxadiazole derivatives for controlling endoparasites | BAYER AG (DE) | 1997-06-04 | — | — | EP | disclosed |
| EP-0767782-A1 | ARYL AND HETEROARYL ALKOXYNAPHTHALENE DERIVATIVES | PFIZER INC. (US) | 1997-04-16 | — | — | EP | disclosed |
| WO-1996000720-A1 | ARYL AND HETEROARYL ALKOXYNAPHTHALENE DERIVATIVES | PFIZER INC. (US) | 1996-01-11 | — | — | WO | disclosed |
| US-5428047-A | Nematocides | BAYER AKTIENGESELLSCHAFT (DE) | 1995-06-27 | — | — | US | disclosed |
| EP-0590415-A2 | 1,2,4-Oxadiazole derivatives for controlling endoparasites | BAYER AG (DE) | 1994-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1S, CACNA1D | SMN1; SMN2 756/4885GAA 3281/4885L3MBTL1 1998/4885 |
| US-20010021718-A1 | Procollagen C-proteinase inhibitors | MMP1, CTSL, PREP | SMN1; SMN2 3907/4885GAA 1264/4885L3MBTL1 2347/4885 |
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | GRIN1, GRM1, GRIK1 | SMN1; SMN2 3616/4885GAA 4077/4885L3MBTL1 4436/4885 |
| US-20050154012-A1 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP3, CASP1, CASP4 | SMN1; SMN2 3329/4885GAA 3337/4885L3MBTL1 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.